GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Salmeterol/Fluticasone propionate
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2014-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 762
- Registration Number
- NCT00662805
Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects
Phase 2
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine GSK134612 (Nimenrix)
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2018-12-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 271
- Registration Number
- NCT00661557
- Locations
- 🇱🇧
GSK Investigational Site, Beirut, Lebanon
Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops
Phase 1
Completed
- Conditions
- Macular Degeneration
- Interventions
- Drug: Ketoconozole tablets
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00659555
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Phase 1
Completed
- Conditions
- Neoplasms, Ovarian
- Interventions
- Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT00659178
- Locations
- 🇺🇸
GSK Investigational Site, Philadelphia, Pennsylvania, United States
A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744
Phase 1
Completed
- Conditions
- HIV Infection
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 58
- Registration Number
- NCT00659191
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT00657020
Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine
Phase 4
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Engerix™-B
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT00657657
- Locations
- 🇹🇭
GSK Investigational Site, Bangkok, Thailand
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 124
- Registration Number
- NCT00655824
- Locations
- 🇬🇧
GSK Investigational Site, Ipswich, United Kingdom
Effectiveness of Human Rotavirus Vaccine, Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants
Completed
- Conditions
- Rotavirus Severe Gastroenteritis
- Interventions
- Other: Collection of informationProcedure: Collection of stool samples
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1270
- Registration Number
- NCT00655187
- Locations
- 🇸🇬
GSK Investigational Site, Singapore, Singapore
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
Phase 3
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: Engerix BBiological: HPV Vaccine (GSK580299) Cervarix TM
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 744
- Registration Number
- NCT00652938
- Locations
- 🇸🇪
GSK Investigational Site, Skene, Sweden
© Copyright 2025. All Rights Reserved by MedPath